Cambria Cannabis ETF - $TOKE Chart Analysis
TAKE A HIT OR LET IT SIT?
On the weekly chart,
TOKE has sold out of the alternative semi-correction which has lead the price action south to the 5th wave of the semi-cycle pivot. MACD divergence seems to be peaking through the weekly signals, applying towards the 4th-5th alternative correction timeframe and assume this divergence will continue displaying throughout the primary 5th wave.
Since the ticker tag is under $10.19, I believe the semi-cycle correction is done and over with and will be on the south side of town until the 5th of the primary cycle target, which I think will start to gain traction around $8.35 -- $7.63 (wave 1 polar) possible floor for cycle correction.
*Bonus thought: This seems to be selling without Aug. and leading into Sept. With Cambria Cannabis ETF holding a lot of Canadian stocks, one might think this continues to sell when the US cannabis stocks are ready to make a correction move in Aug.
On the weekly chart,
TOKE has sold out of the alternative semi-correction which has lead the price action south to the 5th wave of the semi-cycle pivot. MACD divergence seems to be peaking through the weekly signals, applying towards the 4th-5th alternative correction timeframe and assume this divergence will continue displaying throughout the primary 5th wave.Since the ticker tag is under $10.19, I believe the semi-cycle correction is done and over with and will be on the south side of town until the 5th of the primary cycle target, which I think will start to gain traction around $8.35 -- $7.63 (wave 1 polar) possible floor for cycle correction.
*Bonus thought: This seems to be selling without Aug. and leading into Sept. With Cambria Cannabis ETF holding a lot of Canadian stocks, one might think this continues to sell when the US cannabis stocks are ready to make a correction move in Aug.
Related publications
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.